A Search Service for Abbreviation / Long Form

■ Related PubMed/MEDLINE Info.

[Related PubMed/MEDLINE]
Total Number of Papers: 70
[Display Entries]
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation : EAMG
Long Form : experimental autoimmune MG
No. Year Title Co-occurring Abbreviation
2021 Immunoregulatory Cells in Myasthenia Gravis. MDSCs, MG
2020 Decreased expression of miR-29 family associated with autoimmune myasthenia gravis. AChR, MG, TECs
2020 Effects of Teriflunomide on B Cell Subsets in MuSK-Induced Experimental Autoimmune Myasthenia Gravis and Multiple Sclerosis. CFA, MG, MS, MuSK
2018 Heterogeneity of auto-antibodies against nAChR in myasthenic serum and their pathogenic roles in experimental autoimmune myasthenia gravis. MG, MIR, nAChR
2018 Introducing Autoimmunity at the Synapse by a Novel Animal Model of Experimental Autoimmune Myasthenia Gravis. auto-Abs, autoAgs, MG, NMJ
2017 Characterization of a reproducible rat EAMG model induced with various human acetylcholine receptor domains. AChR, ECDs, MG
2017 Injection of inactive Bordetella pertussis and complete Freund's adjuvant with Torpedo californica AChR increases the occurrence of experimental autoimmune myasthenia gravis in C57BL/6 mice. Ab, AChR, CFA, iBP, MG
2017 Myasthenia gravis: the role of complement at the neuromuscular junction. AChR, GMG, MACs, NMJ
2017 Rapamycin alleviates inflammation and muscle weakness, while altering the Treg/Th17 balance in a rat model of myasthenia gravis. MG, RAPA, Treg
10  2016 Animal models of myasthenia gravis: utility and limitations. AChR, MG
11  2016 Differential RNA Expression Profile of Skeletal Muscle Induced by Experimental Autoimmune Myasthenia Gravis in Rats. DIA, EOM, MG
12  2016 Novel CXCL13 transgenic mouse: inflammation drives pathogenic effect of CXCL13 in experimental myasthenia gravis. GCs, MG, Tg
13  2016 Review on Toll-Like Receptor Activation in Myasthenia Gravis: Application to the Development of New Experimental Models. AChR, CFA, IFN, LPS, MG, Mtb, TLR
14  2015 IL-6 and Akt are involved in muscular pathogenesis in myasthenia gravis. AChR, IGF-1, IL-6, MG
15  2015 Severity of Myasthenia Gravis Influences the Relationship between Train-of-four Ratio and Twitch Tension and Run-down of Rat Endplate Potentials. MG, NMBAs, TOFR
16  2014 Delivery of an miR155 inhibitor by anti-CD20 single-chain antibody into B cells reduces the acetylcholine receptor-specific autoantibodies and ameliorates experimental autoimmune myasthenia gravis. Ig, MG, miR-155, NF, PBMCs, TAChR
17  2014 Targeting complement system to treat myasthenia gravis. AChR, CCP, DAF, MAC, MG, NMJ, siRNA
18  2013 Identification of novel MicroRNA signatures linked to experimental autoimmune myasthenia gravis pathogenesis: down-regulated miR-145 promotes pathogenetic Th17 cell response. DC, MG, PBMC
19  2013 Impairment of regulatory T cells in myasthenia gravis: studies in an experimental model. AChR, MG
20  2013 Muscle-specific regulation of the mTOR signaling pathway in MuSK antibody seropositive (MuSK+) experimental autoimmune Myasthenia gravis (EAMG). MG, TA
21  2012 Fatigue and muscle atrophy in a mouse model of myasthenia gravis is paralleled by loss of sarcolemmal nNOS. MG, nNOS
22  2012 Myasthenogenicity of the main immunogenic region. AChBP, AChRs, MG, MIR
23  2012 Regulatory T cell-based immunotherapies in experimental autoimmune myasthenia gravis. MG, reg
24  2011 Acetylcholine receptor-induced experimental myasthenia gravis: what have we learned from animal models after three decades? AChR, autoAbs, MG
25  2011 Amelioration of experimental autoimmune myasthenia gravis rats by blood purification treatment using 4-mercaptoethylpyridine-based adsorbent. MEP, MG
26  2011 Antibodies against muscle-specific kinase impair both presynaptic and postsynaptic functions in a murine model of myasthenia gravis. AChE, AChRs, MG, MuSK, NMJs
27  2011 Elevated serum level of interleukin-32α in the patients with myasthenia gravis. AChR, IL-32, MG, NK, TNF
28  2011 Genetic deficiency of estrogen receptor alpha fails to influence experimental autoimmune myasthenia gravis pathogenesis. AChR, ERalpha, KO, MG, WT
29  2011 Muscle-selective synaptic disassembly and reorganization in MuSK antibody positive MG mice. AChR, MG, YFP
30  2011 Myasthenogenicity of the main immunogenic region and endogenous muscle nicotinic acetylcholine receptors. AChBP, AChRs, MG, MIR
31  2009 Suppression of experimental autoimmune myasthenia gravis by inhibiting the signaling between IFN-gamma inducible protein 10 (IP-10) and its receptor CXCR3. IP-10, MG
32  2008 A disease-specific fraction isolated from IVIG is essential for the immunosuppressive effect of IVIG in experimental autoimmune myasthenia gravis. IVIG, MG
33  2008 Extraocular muscle susceptibility to myasthenia gravis: unique immunological environment? AChR, EOM, MG
34  2008 Immunosuppression of EAMG by IVIG is mediated by a disease-specific anti-immunoglobulin fraction. IVIG, MG
35  2008 Immunosuppression of experimental autoimmune myasthenia gravis by mycophenolate mofetil. AChRs, MG, MMF
36  2008 Myasthenia gravis and the tops and bottoms of AChRs: antigenic structure of the MIR and specific immunosuppression of EAMG using AChR cytoplasmic domains. AChRs, mAbs, MG, MIR
37  2008 Suppression of experimental autoimmune myasthenia gravis by combination therapy: pentoxifylline as a steroid-sparing agent. MG, PDE, PTX
38  2008 Suppression of experimental myasthenia gravis by a B-cell epitope-free recombinant acetylcholine receptor. AChR, BF-AChR, MG
39  2007 A dual altered peptide ligand inhibits myasthenia gravis associated responses by inducing phosphorylated extracellular-regulated kinase 1,2 that upregulates CD4+CD25+Foxp3+ cells. APL, ERK, FOXP3, IFN, LN, MG
40  2007 DNA microarray in search of new drug targets for myasthenia gravis. LNC, MG
41  2007 Suppression of experimental autoimmune myasthenia gravis by intravenous immunoglobulin and isolation of a disease-specific IgG fraction. IVIG, MG
42  2006 A 50-kDa ERK-like protein is up-regulated by a dual altered peptide ligand that suppresses myasthenia gravis-associated responses. APL, MG
43  2006 A dual altered peptide ligand down-regulates myasthenogenic T cell responses and reverses experimental autoimmune myasthenia gravis via up-regulation of Fas-FasL-mediated apoptosis. APL, MG
44  2006 Complement membrane attack is required for endplate damage and clinical disease in passive experimental myasthenia gravis in Lewis rats. AChR, MAC, MG
45  2006 Down-regulation of T cell responses to AChR and reversal of EAMG manifestations in mice by a dual altered peptide ligand via induction of CD4+ CD25+ regulatory cells. APL, MG, TAChR
46  2006 Intravenous immunoglobulin suppresses experimental myasthenia gravis: immunological mechanisms. IVIG, MG
47  2005 Overexpression of IFN-induced protein 10 and its receptor CXCR3 in myasthenia gravis. AChR, IP-10, MG
48  2005 Overexpression of phosphodiesterases in experimental autoimmune myasthenia gravis: suppression of disease by a phosphodiesterase inhibitor. AChR, LNC, MG, PDE, PTX
49  2004 Complement regulators in extraocular muscle and experimental autoimmune myasthenia gravis. AChR, Crry, DAF, EOM, mAb, MG
50  2003 Experimental autoimmune myasthenia gravis in mice expressing human immunoglobulin loci. Abs, AChR, MG, TAChR
51  2003 Genetic evidence for involvement of classical complement pathway in induction of experimental autoimmune myasthenia gravis. AChR, MG
52  2003 Prevention of passively transferred experimental autoimmune myasthenia gravis by an in vitro selected RNA aptamer. AChR, MG
53  2003 The role of readthrough acetylcholinesterase in the pathophysiology of myasthenia gravis. MG
54  2002 Mapping myasthenia gravis-associated T cell epitopes on human acetylcholine receptors in HLA transgenic mice. H-AChR, MG
55  2002 Vaccination with a MHC class II peptide attenuates cellular and humoral responses against tAChR and suppresses clinical EAMG. Ab, MG, tAChR
56  2001 Blockade of CD40 ligand suppresses chronic experimental myasthenia gravis by down-regulation of Th1 differentiation and up-regulation of CTLA-4. AChR, CD40L, MG
57  2001 The nature of the active suppression of responses associated with experimental autoimmune myasthenia gravis by a dual altered peptide ligand administered by different routes. AChR, APL, MG, TAChR, Th
58  2000 Cytokine profile and T cell adhesiveness to endothelial selectins: in vivo induction by a myasthenogenic T cell epitope and immunomodulation by a dual altered peptide ligand. APL, MG
59  2000 Effects of sex hormones on experimental autoimmune myasthenia gravis. AChR Ab, MG, REMG
60  2000 Mechanism of nasal tolerance induced by a recombinant fragment of acetylcholine receptor for treatment of experimental myasthenia gravis. AChR, MG
61  2000 Oral administration of a dual analog of two myasthenogenic T cell epitopes down-regulates experimental autoimmune myasthenia gravis in mice. AChR, MG
62  2000 Prevention of passively transferred experimental autoimmune myasthenia gravis by a phage library-derived cyclic peptide. AcChoR, MG, MIR
63  2000 Specific vaccines against autoimmune diseases. AChR, EAE, MG, MS
64  1999 Myasthenia gravis and its animal model: T cell receptor expression in an antibody mediated autoimmune disease. AChR, MG
65  1998 T cell responses in EAMG-susceptible and non-susceptible mouse strains after immunization with overlapping peptides encompassing the extracellular part of Torpedo californica acetylcholine receptor alpha chain. Implication to role in myasthenia gravis of autoimmune T-cell responses against receptor degradation products. AChR, bm12, MG
66  1997 Autoimmune responses against acetylcholine receptor: T and B cell collaboration and manipulation by synthetic peptides. Abs, AChR, MG
67  1992 Passive transfer of experimental myasthenia gravis via antigenic modulation of acetylcholine receptor. AChR, mAb, MG, MIR
68  1988 Specificity of the T cell immune response to acetylcholine receptor in experimental autoimmune myasthenia gravis. Response to subunits and synthetic peptides. AChR, MG
69  1981 Influence of alpha-fetoprotein on the in vitro and in vivo immune response to acetylcholine receptor. AChR, AFP, MG
70  1980 Dimethyl sulphoxide reduces anti-receptor antibody titres in experimental myasthenia gravis. AChRs, DMSO, MG